lp-168
Small moleculeexperimental
Clinical trial activity
9 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 6, 2021 (NCT04993690)
Timeline
Indications
Studied for
- Leukemia, Hairy Cell · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Sclerosis · Phase 1
- Neuromyelitis Optica · Phase 1
- Pharmacology, Clinical · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)Nc1cc(Nc2nc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)ccc1N1CCN(C2CCOCC2)C[C@@H]1C- Mol. weight
- 761.93 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314539 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07189065 | Phase 2 | Sep 30, 2025 | Guangzhou Lupeng Pharmaceutical Company LTD. |
| NCT06978088 | Phase 2 | Jun 1, 2025 | Newave Pharmaceutical Inc, University of Cincinnati |
| NCT06251180 | Phase 1 | Apr 10, 2024 | Guangzhou Lupeng Pharmaceutical Company LTD., Sun Yat-Sen University |
| NCT06126861 | Phase 1 | Dec 1, 2023 | Guangzhou Lupeng Pharmaceutical Company LTD., Soochow University |
| NCT05917964 | Phase 1 | Jun 21, 2023 | Guangzhou Lupeng Pharmaceutical Company LTD., Zhejiang University |
| NCT05716087 | Phase 2 | Feb 21, 2023 | Guangzhou Lupeng Pharmaceutical Company LTD., Peking University |
| NCT05432713 | Phase 1 | May 14, 2022 | Guangzhou Lupeng Pharmaceutical Company LTD., Zhejiang University |
| NCT04775745 | Phase 1 | Jul 19, 2021 | Newave Pharmaceutical Inc |
| NCT04993690 | Phase 1 | Jul 6, 2021 | Chinese Academy of Medical Sciences, Guangzhou Lupeng Pharmaceutical Company LTD. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guangzhou Lupeng Pharmaceutical Company LTD. | For profit | 7 | 7 | 2 | 2021 |
| Newave Pharmaceutical Inc | For profit | 2 | 1 | 2 | 2021 |
| Zhejiang University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Cincinnati | Academic/Hospital | 1 | 1 | 1 | 2025 |
8 organizations
Page 1 / 1